PMID- 32874058
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 26
IP  - 30
DP  - 2020 Aug 14
TI  - Efficacy and safety of lenvatinib for patients with advanced hepatocellular 
      carcinoma: A retrospective, real-world study conducted in China.
PG  - 4465-4478
LID - 10.3748/wjg.v26.i30.4465 [doi]
AB  - BACKGROUND: Lenvatinib has become an indispensable part of treatment regimens for 
      patients with advanced hepatocellular carcinoma (aHCC). Several recent real-world 
      studies appear to have confirmed this; however, there are etiological 
      differences. This necessitates further real-world studies of lenvatinib across 
      diverse populations, such as in China. AIM: To investigate the efficacy and 
      safety of lenvatinib in a Chinese HCC patient population under real-world 
      conditions. METHODS: This is a retrospective and multiregional study involving 
      patients with aHCC receiving lenvatinib monotherapy. Efficacy was assessed using 
      the Response Evaluation Criteria in Solid Tumors version 1.1. Baseline 
      characteristics and adverse events (AEs) were recorded throughout the entire 
      study. RESULTS: In total, 54 HCC patients treated with lenvatinib monotherapy 
      were included for final analysis. The objective response rate was 22% (n = 12) 
      with a progression-free survival (PFS) of 168 d; however, AEs occurred in 92.8% 
      of patients. Multivariate analysis showed that the Barcelona Clinic Liver Cancer 
      stage [hazard ratio (HR) 0.465; 95%CI: 0.23-0.93; P = 0.031], portal vein tumor 
      thrombus (HR 0.38; 95%CI: 0.15-0.94; P = 0.037) and Child-Pugh classifications 
      (HR 0.468; 95%CI: 0.22-0.97; P = 0.042) were significant factors affecting PFS. 
      The sensitivity (56.7%) and specificity (83.3%) of decreasing serum biomarkers 
      including alpha-fetoprotein were calculated in order to predict tumor size 
      reduction. Gene sequencing also provided insights into potential gene mutation 
      signatures related to the effect of lenvatinib. CONCLUSION: Our findings confirm 
      previous evidence from the phase III REFLECT study. The majority of patients in 
      this Chinese sample were suffering from concomitant hepatitis B virus-related 
      HCC. However, further analysis suggested that baseline characteristics, changes 
      in serum biomarkers and gene sequencing may hold the key for predicting 
      lenvatinib responses. Further large-scale prospective studies that incorporate 
      more basic medical science measures should be conducted.
CI  - (c)The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - Wang, Dong-Xu
AU  - Wang DX
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, 
      China.
FAU - Yang, Xu
AU  - Yang X
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, 
      China.
FAU - Lin, Jian-Zhen
AU  - Lin JZ
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, 
      China.
FAU - Bai, Yi
AU  - Bai Y
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, 
      China.
FAU - Long, Jun-Yu
AU  - Long JY
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, 
      China.
FAU - Yang, Xiao-Bo
AU  - Yang XB
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, 
      China.
FAU - Seery, Samuel
AU  - Seery S
AD  - Department of Humanities, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
FAU - Zhao, Hai-Tao
AU  - Zhao HT
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, 
      China. zhaoht@pumch.cn.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Quinolines)
RN  - EE083865G2 (lenvatinib)
SB  - IM
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - China/epidemiology
MH  - Humans
MH  - *Liver Neoplasms/drug therapy
MH  - Phenylurea Compounds/adverse effects
MH  - Quinolines
MH  - Retrospective Studies
PMC - PMC7438196
OTO - NOTNLM
OT  - Efficacy
OT  - Hepatocellular carcinoma
OT  - Lenvatinib
OT  - Real-world study
OT  - Safety
OT  - Treatment
COIS- Conflict-of-interest statement: The authors declare that they have no competing 
      interests.
EDAT- 2020/09/03 06:00
MHDA- 2021/05/15 06:00
PMCR- 2020/08/14
CRDT- 2020/09/03 06:00
PHST- 2020/03/14 00:00 [received]
PHST- 2020/04/25 00:00 [revised]
PHST- 2020/07/04 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/08/14 00:00 [pmc-release]
AID - 10.3748/wjg.v26.i30.4465 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2020 Aug 14;26(30):4465-4478. doi: 
      10.3748/wjg.v26.i30.4465.